Form 604

Corporations Act 2001 Section 671B

Notice of change of interests of substantial holder

To Company Name/Scheme CYCLOPHARM LIMITED

ACN/ARSN 116 931 250

1. Details of substantial holder (1)

Name LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED

ACN/ARSN (if applicable)

There was a change in the interests of the

substantial holder on

30/4/2013

The previous notice was given to the company on

21/12/2012

The previous notice was dated

21/12/2012

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
ORDINARY	9,717,600	16.7%	10,186,974	17.7%
			į.	

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
	REFER TO ANNEXURE A				
			4		

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of	Registered holder of securities	Person entitled to be	Nature of relevant interest (6)	Class and number of securities	Person's votes
relevant interest	or securities	registered as holder (8)	linterest (6)	or securities	
Lloyds &	Lloyds &	Lloyds &			
Casanove	Casanove	Casanove			
Investment	Investment	Investment		Ordinary	10,186,974
Partners	Partners	Partners			
Limited	Limited	Limited			



· ·			
		· ·	

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
NOT APPLICABLE	

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED	RUSSELL BEDFORD HOUSE, CITY FORUM, 250 CITY ROAD, LONDON ECIV2Q9, ENGLAND

Signature

print name

Capacity DIRECTOR

sign here

105/2013 date

DIRECTIONS

- If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- See the definition of "associate" in section 9 of the Corporations Act 2001.
- See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- The voting shares of a company constitute one class unless divided into separate classes. (4)
- The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- Include details of: (6)
 - any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and (a) accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification (b) applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

(9)	Give details, if appropriate, of the present association and any change in that association since the last substantial holding	g notice.

ANNEXURE A

This is Annexure A Page 1 of 1 - Cyclopharm Limited (ACN: 116 931 250)

3 Changes in relevant interests

Date of change	Person whose relevant interest changed	Nature of change	Consideration given in relation to change	Class and number of Person's securities affected affected affected	Person's votes affected
18.02.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 281	1,999	
25.02.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 8,621	57,472	
27.02.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 6,110	40,529	
02.04.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 14,598	121,041	
17.04.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 7,504	53,333	
30.04.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 35,293	195,000	
				2	3
		· ·			
Total			\$ 72,406	469,374	

Signed: 19 M Date: 1 may 2013